Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: Results of an international survey

Leukemia and Lymphoma

Volumn 25, Issue 5-6, 1997, Pages 487-491

  Grigg, Andrew ^a   Harun, Mohd Hishamuddin ^a   Szer, Jeff ^a  

^a Department of Clinical Haematology ^*  (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE;

ADULT; ARTICLE; BODY WEIGHT; BONE MARROW TRANSPLANTATION; DRUG EFFICACY; DRUG TOXICITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 0030746124     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709039036     Document Type: Article

References (20)

1. Santos, G. W., Tutschka, P. J., Brookmeyer, R. et al. (1983). Marrow transplantation for acute nonlymphocytic leukaemia after treatment with busulfan and cyclophosphamide, N. Engl. J. Med., 309, 1347-1352.
2. Nevill, T. J., Barnett, M. J., Kungemann, H. G., Reece, D. E., Shepherd, J. D. and Phillips, G. L (1991). Regimen-related toxicity of busulfan-cyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J. Clin Oncol., 9, 1224-1232.
3. Rosenthal, M A , Grigg, A P. and Sheridan, W. P. (1994). High dose busulphan/cyclophosphamide for autologous bone marrow transplantation is associated with minimal non-hemopoietic toxicity. Leuk. Lymphoma, 14, 279-283.
4. Clift, R. A., Buckner, C. D., Thomas, E. D. et al. (1994). Marrow transplantation for chronic myeloid leukaemia: A randomised study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide, Blood, 84, 2036-2043
5. Kusnierz-Glaz, C. R , Coghlin, T., Schlegel, P. G. et al. (1995). Impact of admission body weight and dose adjusting in outcome of 500 patients with hematological malignancies post autologous transplantation. Blood, 86, (abstract no. 1590).
6. Zarowitz, B. J., Peterson, E. and Popovich, J. (1989). Relationship of bioelectrical impedance to pharmacokinetic parameters of theophylline in health males. Clin. Pharmacokinet., 17, 200-207.
7. Martin, E. S., Crismon, M. L. and Godley, P. L. (1991). Postinduction carbamazepine clearance in a adult psychiatric population, Pharmacotherapy, 11, 296-302.
8. Hassan, M., Oberg, G., Ehrsson, H. et al. (1989). Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur. J. Clin Pharmacol., 36, 525-530.
9. Bray, G A (1987) Overweight is risking fate definition, classification, prevalence and risks, Ann. NY Acad. Sci., 499, 14-28.
10. Lukasi, H. C., Johnson, P. E., Bolonchuk, W. W. and Lykken, G. I. (1985). Assessment of fat-free mass using B1 measurements of the human body, Amer. J Clin. Nutrition, 41, 810-817.
11. Roubenoff, R. and Kehayias, J. J. (1991). The meaning and measurement of lean body mass. Nutrition Reviews, 49, 163-175.
12. Roberts, C. J. C., Jackson, L., Halliwell, M. and Branch, M (1976) The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobaritone administration in man, Br. J. Clin. Pharmac., 3, 907-913.
13. Angus, P. Department of Gastroenterology, Austin Repatriation Medical Centre, Heidelberg. Victoria, Australia (personal communication).
14. Grochow, L. B. (1993). Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens, Sem. Oncol., 20, 18-25.
15. Hassan, M., Ljungman, P., Bolme, P. et al. (1994). Busulfan bioavailability, Blood, 84, 2144-2150.
16. Dix, S P., Mullins, R. E., Jerkunica, I. et al. (1993). Association of busulfan area under the curve (AUC) with veno-occlusive disease (VOD) following bone marrow transplantation (BMT), Blood, 82, 418a (abstract no. 1658).
17. Schuler, U., Schroer, S., Kuhnle, A. et al. (1994). Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted?. Bone Marrow Transplant, 14, 759-765.
18. Hassan, M., Oberg, G., Bjorkholm, M., Wallin, I and Lindgren, M. (1993). Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics, Cancer Chemo. Pharmacol., 33, 181-186.
19. Kasaim, Kiyama, Y., Watanabe, M. et al. (1992). Toxcity of high-dose busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation, Transplant. Proc., 24, 1529-1530.
20. Storb, R., Deeg, H J., Whitehead, J. et al. (1986). Methotrexate and cyclosporin compared with cyclosporin alone for prophylaxis of acute graft-vs-host disease after marrow transplantation for leukaemia. New Engl J. Med., 314, 729-735.